Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-629.09%
operating margin TTM
-618.34%
revenue TTM
411.33 Million
revenue per share TTM
0.27$
valuation ratios | |
|---|---|
| pe ratio | -0.08 |
| peg ratio | 0.00 |
| price to book ratio | -0.18 |
| price to sales ratio | 3.11 |
| enterprise value multiple | -0.38 |
| price fair value | -0.18 |
profitability ratios | |
|---|---|
| gross profit margin | 86.02% |
| operating profit margin | -618.34% |
| pretax profit margin | -607.65% |
| net profit margin | -629.09% |
| return on assets | -116.46% |
| return on equity | 472.78% |
| return on capital employed | -189.0% |
liquidity ratios | |
|---|---|
| current ratio | 1.52 |
| quick ratio | 1.29 |
| cash ratio | 0.51 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 1,232.25 |
| operating cycle | 1,668.35 |
| days of payables outstanding | 1,017.03 |
| cash conversion cycle | 651.32 |
| receivables turnover | 0.84 |
| payables turnover | 0.36 |
| inventory turnover | 0.30 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.37 |
| debt equity ratio | -0.69 |
| long term debt to capitalization | -0.57 |
| total debt to capitalization | -2.19 |
| interest coverage | -32.82 |
| cash flow to debt ratio | -2.79 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.52 |
| cash per share | 0.10 |
| operating cash flow per share | -0.51 |
| free cash flow operating cash flow ratio | 1.01 |
| cash flow coverage ratios | -2.79 |
| short term coverage ratios | -30.03 |
| capital expenditure coverage ratio | -55.31 |
Frequently Asked Questions
When was the last time Adaptimmune Therapeutics plc (NASDAQ:ADAP) reported earnings?
Adaptimmune Therapeutics plc (ADAP) published its most recent earnings results on 13-08-2025.
What is Adaptimmune Therapeutics plc's current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Adaptimmune Therapeutics plc (NASDAQ:ADAP)'s trailing twelve months ROE is 472.78%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Adaptimmune Therapeutics plc (ADAP) currently has a ROA of -116.46%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did ADAP's net profit margin stand at?
ADAP reported a profit margin of -629.09% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is ADAP's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 1.52 in the most recent quarter. The quick ratio stood at 1.29, with a Debt/Eq ratio of -0.69.